Bill Trombetta


20th Annual Industry Audit: Year of the Pandemic

Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.

Pharm Exec’s 19th Annual Industry Audit

Our latest review of biopharma financial performance reveals solid growth rates in enterprise value and rebounding value-to-sales numbers—proving once again the business imperative of regaining and sustaining shareholder value.

Pharm Exec's 18th Annual Industry Audit

Pharm Exec’s latest analysis of financial performance reveals that it’s those drugmakers maximizing the difference between the value and the cost of their capital investments that are delivering the most bang for the buck to shareholders.

Pharm Exec's 16th Annual Industry Audit

With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.